;PMID: 11755311
;source_file_820.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..142] = [t:49..142]
;2)section:[e:146..198] = [t:146..198]
;3)section:[e:202..338] = [t:202..338]
;4)sentence:[e:342..590] = [t:342..590]
;5)sentence:[e:591..700] = [t:591..700]
;6)sentence:[e:701..855] = [t:701..855]
;7)sentence:[e:856..1044] = [t:856..1044]
;8)sentence:[e:1046..1181] = [t:1046..1181]
;9)sentence:[e:1182..1271] = [t:1182..1271]
;10)sentence:[e:1272..1452] = [t:1272..1452]
;11)sentence:[e:1453..1584] = [t:1453..1584]
;12)sentence:[e:1585..1749] = [t:1585..1749]
;13)sentence:[e:1751..1969] = [t:1751..1969]
;14)sentence:[e:1970..2151] = [t:1970..2151]
;15)section:[e:2155..2200] = [t:2155..2200]

;section 0 Span:0..43
;Free Radic Biol Med. 2002 Jan 1;32(1):2-10.
(SEC
  (FRAG (RB:[0..4] Free) (NNP:[5..10] Radic) (NNP:[11..15] Biol)
        (NNP:[16..19] Med) (.:[19..20] .) ('':[21..25] 2002) (NNP:[26..29] Jan)
        (CD:[30..35] 1;32-LRB-) (CD:[35..36] 1) (-RRB-:[36..37] -RRB-)
        (CD:[37..39] :2) (NN:[39..40] -) (CD:[40..42] 10) (.:[42..43] .)))

;sentence 1 Span:49..142
;Endogenous and endobiotic induced reactive oxygen species formation by
;isolated  hepatocytes.
;[83..106]:substance:"reactive oxygen species"
(SENT
  (NP-HLN
    (NP
      (NP
        (NML (JJ:[49..59] Endogenous)
          (NML-2 (-NONE-:[59..59] *P*)))
        (NML-3 (-NONE-:[59..59] *P*)))
      (CC:[60..63] and)
      (NP
        (NML
          (ADJP (JJ:[64..74] endobiotic) (VBN:[75..82] induced))
          (NML-2 (JJ:[83..91] reactive) (NN:[92..98] oxygen)
                 (NN:[99..106] species)))
        (NML-3 (NN:[107..116] formation))))
    (PP (IN:[117..119] by)
      (NP (VBN:[120..128] isolated) (NNS:[130..141] hepatocytes)))
    (.:[141..142] .)))

;section 2 Span:146..198
;Siraki AG, Pourahmad J, Chan TS, Khan S, O'Brien PJ.
(SEC
  (FRAG (NNP:[146..152] Siraki) (NNP:[153..155] AG) (,:[155..156] ,)
        (NNP:[157..166] Pourahmad) (NNP:[167..169] J,) (NNP:[170..174] Chan)
        (NNP:[175..177] TS) (,:[177..178] ,) (NNP:[179..183] Khan)
        (NNP:[184..186] S,) (NNP:[187..194] O'Brien) (NNP:[195..198] PJ.)))

;section 3 Span:202..338
;Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of 
;Toronto, 19 Russell Street, Toronto, Ontario, Canada M5S 2S2.
(SEC
  (FRAG (NNP:[202..212] Department) (IN:[213..215] of)
        (NNP:[216..230] Pharmaceutical) (NNPS:[231..239] Sciences)
        (,:[239..240] ,) (NNP:[241..248] Faculty) (IN:[249..251] of)
        (NNP:[252..260] Pharmacy) (,:[260..261] ,) (NNP:[262..272] University)
        (IN:[273..275] of) (NNP:[277..284] Toronto) (,:[284..285] ,)
        (CD:[286..288] 19) (NNP:[289..296] Russell) (NNP:[297..303] Street)
        (,:[303..304] ,) (NNP:[305..312] Toronto) (,:[312..313] ,)
        (NNP:[314..321] Ontario) (,:[321..322] ,) (NNP:[323..329] Canada)
        (NNP:[330..333] M5S) (NNP:[334..337] 2S2) (.:[337..338] .)))

;sentence 4 Span:342..590
;The rat hepatocyte catalyzed oxidation of 2',7'-dichlorofluorescin to form
;the  fluorescent 2,7'-dichlorofluorescein was used to measure endogenous and 
;xenobiotic-induced reactive oxygen species (ROS) formation by intact isolated
; rat hepatocytes.
;[384..408]:substance:"2',7'-dichlorofluorescin"
;[434..458]:substance:"2,7'-dichlorofluorescein"
;[514..537]:substance:"reactive oxygen species"
;[539..542]:substance:"ROS"
(SENT
  (S
    (NP-SBJ-5
      (NP
        (NP (DT:[342..345] The)
          (ADJP
            (NML (NN:[346..349] rat) (NN:[350..360] hepatocyte))
            (VBN:[361..370] catalyzed))
          (NN:[371..380] oxidation))
        (PP (IN:[381..383] of)
          (NP (NN:[384..408] 2',7'-dichlorofluorescin))))
      (SBAR
        (WHNP-4 (-NONE-:[408..408] 0))
        (S
          (NP-SBJ-4 (-NONE-:[408..408] *T*))
          (VP (TO:[409..411] to)
            (VP (VB:[412..416] form)
              (NP (DT:[417..420] the) (JJ:[422..433] fluorescent)
                  (NN:[434..458] 2,7'-dichlorofluorescein)))))))
    (VP (VBD:[459..462] was)
      (VP (VBN:[463..467] used)
        (NP-5 (-NONE-:[467..467] *))
        (S-PRP
          (NP-SBJ (-NONE-:[467..467] *))
          (VP (TO:[468..470] to)
            (VP (VB:[471..478] measure)
              (NP
                (NP
                  (NP (JJ:[479..489] endogenous)
                    (NML-2 (-NONE-:[489..489] *P*))
                    (NML-3 (-NONE-:[489..489] *P*)))
                  (CC:[490..493] and)
                  (NP
                    (NML
                      (ADJP (NN:[495..505] xenobiotic) (HYPH:[505..506] -)
                            (VBN:[506..513] induced))
                      (NML-2
                        (NML (JJ:[514..522] reactive) (NN:[523..529] oxygen)
                             (NN:[530..537] species))
                        (NML (-LRB-:[538..539] -LRB-) (NN:[539..542] ROS)
                             (-RRB-:[542..543] -RRB-))))
                    (NML-3 (NN:[544..553] formation))))
                (PP (IN:[554..556] by)
                  (NP (JJ:[557..563] intact) (VBN:[564..572] isolated)
                      (NN:[574..577] rat) (NNS:[578..589] hepatocytes)))))))))
    (.:[589..590] .)))

;sentence 5 Span:591..700
;Various oxidase substrates and inhibitors were then used to  identify the
;intracellular oxidases responsible.
;[599..606]:substance:"oxidase"
;[607..617]:substance:"substrates"
;[622..632]:substance:"inhibitors"
;[679..687]:substance:"oxidases"
(SENT
  (S
    (NP-SBJ-2 (JJ:[591..598] Various)
      (NML
        (NML
          (NML-1 (NN:[599..606] oxidase))
          (NNS:[607..617] substrates))
        (CC:[618..621] and)
        (NML
          (NML-1 (-NONE-:[621..621] *P*))
          (NNS:[622..632] inhibitors))))
    (VP (VBD:[633..637] were)
      (ADVP-TMP (RB:[638..642] then))
      (VP (VBN:[643..647] used)
        (NP-2 (-NONE-:[647..647] *))
        (S-PRP
          (NP-SBJ (-NONE-:[647..647] *))
          (VP (TO:[648..650] to)
            (VP (VB:[652..660] identify)
              (NP
                (NP (DT:[661..664] the) (JJ:[665..678] intracellular)
                    (NNS:[679..687] oxidases))
                (ADJP (JJ:[688..699] responsible))))))))
    (.:[699..700] .)))

;sentence 6 Span:701..855
;Endogenous ROS formation was  markedly increased in catalase-inhibited or
;GSH-depleted hepatocytes, and was  inhibited by ROS scavengers or
;desferoxamine.
;[712..715]:substance:"ROS"
;[753..761]:substance:"catalase"
;[775..778]:substance:"GSH"
;[823..826]:substance:"ROS"
;[827..837]:substance:"scavengers"
;[841..854]:substance:"desferoxamine"
(SENT
  (S
    (NP-SBJ-2 (JJ:[701..711] Endogenous) (NN:[712..715] ROS)
              (NN:[716..725] formation))
    (VP
      (VP (VBD:[726..729] was)
        (ADVP (RB:[731..739] markedly))
        (VP (VBN:[740..749] increased)
          (NP-2 (-NONE-:[749..749] *))
          (PP-LOC (IN:[750..752] in)
            (NP
              (NP
                (ADJP (NN:[753..761] catalase) (HYPH:[761..762] -)
                      (VBN:[762..771] inhibited))
                (NML-1 (-NONE-:[771..771] *P*)))
              (CC:[772..774] or)
              (NP
                (ADJP (NN:[775..778] GSH) (HYPH:[778..779] -)
                      (VBN:[779..787] depleted))
                (NML-1 (NNS:[788..799] hepatocytes)))))))
      (,:[799..800] ,) (CC:[801..804] and)
      (VP (VBD:[805..808] was)
        (VP (VBN:[810..819] inhibited)
          (NP-2 (-NONE-:[819..819] *))
          (PP (IN:[820..822] by)
            (NP-LGS
              (NP (NN:[823..826] ROS) (NNS:[827..837] scavengers))
              (CC:[838..840] or)
              (NP (NN:[841..854] desferoxamine)))))))
    (.:[854..855] .)))

;sentence 7 Span:856..1044
;Endogenous ROS formation was also  inhibited by cytochrome P450 inhibitors,
;but was not affected by oxypurinol, a  xanthine oxidase inhibitor, or
;phenelzine, a monoamine oxidase inhibitor.
;[867..870]:substance:"ROS"
;[904..919]:cyp450:"cytochrome P450"
;[920..930]:substance:"inhibitors"
;[956..966]:substance:"oxypurinol"
;[971..987]:substance:"xanthine oxidase"
;[988..997]:substance:"inhibitor"
;[1002..1012]:substance:"phenelzine"
;[1016..1033]:substance:"monoamine oxidase"
;[1034..1043]:substance:"inhibitor"
(SENT
  (S
    (NP-SBJ-1 (JJ:[856..866] Endogenous) (NN:[867..870] ROS)
              (NN:[871..880] formation))
    (VP
      (VP (VBD:[881..884] was)
        (ADVP (RB:[885..889] also))
        (VP (VBN:[891..900] inhibited)
          (NP-1 (-NONE-:[900..900] *))
          (PP (IN:[901..903] by)
            (NP-LGS
              (NML (NN:[904..914] cytochrome) (NN:[915..919] P450))
              (NNS:[920..930] inhibitors)))))
      (,:[930..931] ,) (CC:[932..935] but)
      (VP (VBD:[936..939] was) (RB:[940..943] not)
        (VP (VBN:[944..952] affected)
          (NP-1 (-NONE-:[952..952] *))
          (PP (IN:[953..955] by)
            (NP-LGS
              (NP
                (NP (NN:[956..966] oxypurinol))
                (,:[966..967] ,)
                (NP (DT:[968..969] a)
                  (NML (NN:[971..979] xanthine) (NN:[980..987] oxidase))
                  (NN:[988..997] inhibitor)))
              (,:[997..998] ,) (CC:[999..1001] or)
              (NP
                (NP (NN:[1002..1012] phenelzine))
                (,:[1012..1013] ,)
                (NP (DT:[1014..1015] a)
                  (NML (NN:[1016..1025] monoamine) (NN:[1026..1033] oxidase))
                  (NN:[1034..1043] inhibitor))))))))
    (.:[1043..1044] .)))

;sentence 8 Span:1046..1181
;Mitochondrial respiratory chain inhibitors or hypoxia, on the other hand, 
;markedly increased ROS formation before cytotoxicity ensued.
;[1078..1088]:substance:"inhibitors"
;[1140..1143]:substance:"ROS"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1046..1059] Mitochondrial)
        (NML (JJ:[1060..1071] respiratory) (NN:[1072..1077] chain))
        (NNS:[1078..1088] inhibitors))
      (CC:[1089..1091] or)
      (NP (NN:[1092..1099] hypoxia)))
    (,:[1099..1100] ,)
    (PP (IN:[1101..1103] on)
      (NP (DT:[1104..1107] the) (JJ:[1108..1113] other) (NN:[1114..1118] hand)))
    (,:[1118..1119] ,)
    (ADVP (RB:[1121..1129] markedly))
    (VP (VBD:[1130..1139] increased)
      (NP (NN:[1140..1143] ROS) (NN:[1144..1153] formation))
      (SBAR-TMP (IN:[1154..1160] before)
        (S
          (NP-SBJ (NN:[1161..1173] cytotoxicity))
          (VP (VBD:[1174..1180] ensued)))))
    (.:[1180..1181] .)))

;sentence 9 Span:1182..1271
;Furthermore,  uncouplers of oxidative phosphorylation inhibited endogenous
;ROS formation.
;[1257..1260]:substance:"ROS"
(SENT
  (S
    (ADVP (RB:[1182..1193] Furthermore))
    (,:[1193..1194] ,)
    (NP-SBJ
      (NP (NNS:[1196..1206] uncouplers))
      (PP (IN:[1207..1209] of)
        (NP (JJ:[1210..1219] oxidative) (NN:[1220..1235] phosphorylation))))
    (VP (VBD:[1236..1245] inhibited)
      (NP (JJ:[1246..1256] endogenous) (NN:[1257..1260] ROS)
          (NN:[1261..1270] formation)))
    (.:[1270..1271] .)))

;sentence 10 Span:1272..1452
;This  suggests endogenous ROS formation can largely be attributed to oxygen
;reduction  by reduced mitochondrial electron transport components and reduced
;cytochrome  P450 isozymes.
;[1298..1301]:substance:"ROS"
;[1341..1347]:substance:"oxygen"
;[1426..1451]:cyp450:"cytochrome  P450 isozymes"
(SENT
  (S
    (NP-SBJ (DT:[1272..1276] This))
    (VP (VBZ:[1278..1286] suggests)
      (SBAR (-NONE-:[1286..1286] 0)
        (S
          (NP-SBJ-1 (JJ:[1287..1297] endogenous) (NN:[1298..1301] ROS)
                    (NN:[1302..1311] formation))
          (VP (MD:[1312..1315] can)
            (ADVP (RB:[1316..1323] largely))
            (VP (VB:[1324..1326] be)
              (VP (VBN:[1327..1337] attributed)
                (NP-1 (-NONE-:[1337..1337] *))
                (PP-CLR (TO:[1338..1340] to)
                  (NP
                    (NP (NN:[1341..1347] oxygen) (NN:[1348..1357] reduction))
                    (PP (IN:[1359..1361] by)
                      (NP
                        (NP (VBN:[1362..1369] reduced)
                            (JJ:[1370..1383] mitochondrial)
                          (NML (NN:[1384..1392] electron)
                               (NN:[1393..1402] transport))
                          (NNS:[1403..1413] components))
                        (CC:[1414..1417] and)
                        (NP (VBN:[1418..1425] reduced)
                          
                          (NML (NN:[1426..1436] cytochrome)
                               (NN:[1438..1442] P450))
                          (NNS:[1443..1451] isozymes))))))))))))
    (.:[1451..1452] .)))

;sentence 11 Span:1453..1584
;Addition of monoamine oxidase substrates increased antimycin  A-resistant
;respiration and ROS formation before cytotoxicity ensued.
;[1465..1482]:substance:"monoamine oxidase"
;[1483..1493]:substance:"substrates"
;[1504..1516]:substance:"antimycin  A"
;[1543..1546]:substance:"ROS"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1453..1461] Addition))
      (PP (IN:[1462..1464] of)
        (NP
          (NML (NN:[1465..1474] monoamine) (NN:[1475..1482] oxidase))
          (NNS:[1483..1493] substrates))))
    (VP (VBD:[1494..1503] increased)
      (NP
        (NP
          (ADJP
            (NML (NN:[1504..1513] antimycin) (NN:[1515..1516] A))
            (HYPH:[1516..1517] -) (JJ:[1517..1526] resistant))
          (NN:[1527..1538] respiration))
        (CC:[1539..1542] and)
        (NP (NN:[1543..1546] ROS) (NN:[1547..1556] formation)))
      (SBAR-TMP (IN:[1557..1563] before)
        (S
          (NP-SBJ (NN:[1564..1576] cytotoxicity))
          (VP (VBD:[1577..1583] ensued)))))
    (.:[1583..1584] .)))

;sentence 12 Span:1585..1749
;Addition  of peroxisomal substrates also increased antimycin A-resistant
;respiration but  they were less effective at inducing ROS formation and were
;not cytotoxic.
;[1610..1620]:substance:"substrates"
;[1636..1647]:substance:"antimycin A"
;[1712..1715]:substance:"ROS"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[1585..1593] Addition))
        (PP (IN:[1595..1597] of)
          (NP (JJ:[1598..1609] peroxisomal) (NNS:[1610..1620] substrates))))
      (ADVP (RB:[1621..1625] also))
      (VP (VBD:[1626..1635] increased)
        (NP
          (ADJP
            (NML (NN:[1636..1645] antimycin) (NN:[1646..1647] A))
            (HYPH:[1647..1648] -) (JJ:[1648..1657] resistant))
          (NN:[1658..1669] respiration))))
    (CC:[1670..1673] but)
    (S
      (NP-SBJ (PRP:[1675..1679] they))
      (VP
        (VP (VBD:[1680..1684] were)
          (ADJP-PRD (RBR:[1685..1689] less) (JJ:[1690..1699] effective)
            (PP (IN:[1700..1702] at)
              (S-NOM
                (NP-SBJ (-NONE-:[1702..1702] *))
                (VP (VBG:[1703..1711] inducing)
                  (NP (NN:[1712..1715] ROS) (NN:[1716..1725] formation)))))))
        (CC:[1726..1729] and)
        (VP (VBD:[1730..1734] were) (RB:[1735..1738] not)
          (ADJP-PRD (JJ:[1739..1748] cytotoxic)))))
    (.:[1748..1749] .)))

;sentence 13 Span:1751..1969
;However, peroxisomal substrates readily induced ROS formation and were
;cytotoxic  towards catalase-inhibited hepatocytes, which suggests that
;peroxisomal catalase  removes endogenous H(2)O(2) formed in the peroxisomes.
;[1772..1782]:substance:"substrates"
;[1799..1802]:substance:"ROS"
;[1841..1849]:substance:"catalase"
;[1905..1913]:substance:"catalase"
;[1934..1942]:substance:"H(2)O(2)"
(SENT
  (S
    (ADVP (RB:[1751..1758] However))
    (,:[1758..1759] ,)
    (NP-SBJ (JJ:[1760..1771] peroxisomal) (NNS:[1772..1782] substrates))
    (ADVP (RB:[1783..1790] readily))
    (VP
      (VP (VBD:[1791..1798] induced)
        (NP (NN:[1799..1802] ROS) (NN:[1803..1812] formation)))
      (CC:[1813..1816] and)
      (VP (VBD:[1817..1821] were)
        (ADJP-PRD (JJ:[1822..1831] cytotoxic)
          (NP (IN:[1833..1840] towards)
            (NP
              (ADJP (NN:[1841..1849] catalase) (HYPH:[1849..1850] -)
                    (VBN:[1850..1859] inhibited))
              (NNS:[1860..1871] hepatocytes))))
        (,:[1871..1872] ,)
        (SBAR-ADV
          (WHNP-1 (WDT:[1873..1878] which))
          (S
            (NP-SBJ-1 (-NONE-:[1878..1878] *T*))
            (VP (VBZ:[1879..1887] suggests)
              (SBAR (IN:[1888..1892] that)
                (S
                  (NP-SBJ (JJ:[1893..1904] peroxisomal)
                          (NN:[1905..1913] catalase))
                  (VP (VBZ:[1915..1922] removes)
                    (NP
                      (NP (JJ:[1923..1933] endogenous)
                          (NN:[1934..1942] H-LRB-2-RRB-O-LRB-2-RRB-))
                      (VP (VBN:[1943..1949] formed)
                        (NP (-NONE-:[1949..1949] *))
                        (PP-LOC (IN:[1950..1952] in)
                          (NP (DT:[1953..1956] the)
                              (NNS:[1957..1968] peroxisomes)))))))))))))
    (.:[1968..1969] .)))

;sentence 14 Span:1970..2151
;Hepatocyte catalyzed  dichlorofluorescin oxidation induced by oxidase
;substrates, e.g., benzylamine,  was correlated with the cytotoxicity induced
;in catalase-inhibited hepatocytes.
;[1992..2010]:substance:"dichlorofluorescin"
;[2032..2039]:substance:"oxidase"
;[2040..2050]:substance:"substrates"
;[2058..2069]:substance:"benzylamine"
;[2120..2128]:substance:"catalase"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (ADJP (NN:[1970..1980] Hepatocyte) (VBN:[1981..1990] catalyzed))
        (NN:[1992..2010] dichlorofluorescin) (NN:[2011..2020] oxidation))
      (VP (VBN:[2021..2028] induced)
        (NP (-NONE-:[2028..2028] *))
        (PP (IN:[2029..2031] by)
          (NP-LGS
            (NP (NN:[2032..2039] oxidase) (NNS:[2040..2050] substrates))
            (,:[2050..2051] ,)
            (NP
              (ADVP (FW:[2052..2056] e.g.))
              (,:[2056..2057] ,) (NN:[2058..2069] benzylamine))))))
    (,:[2069..2070] ,)
    (VP (VBD:[2072..2075] was)
      (VP (VBN:[2076..2086] correlated)
        (NP-1 (-NONE-:[2086..2086] *))
        (PP-CLR (IN:[2087..2091] with)
          (NP
            (NP (DT:[2092..2095] the) (NN:[2096..2108] cytotoxicity))
            (VP (VBN:[2109..2116] induced)
              (NP (-NONE-:[2116..2116] *))
              (PP-LOC (IN:[2117..2119] in)
                (NP
                  (ADJP (NN:[2120..2128] catalase) (HYPH:[2128..2129] -)
                        (VBN:[2129..2138] inhibited))
                  (NNS:[2139..2150] hepatocytes))))))))
    (.:[2150..2151] .)))

;section 15 Span:2155..2200
;PMID: 11755311 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2155..2159] PMID) (::[2159..2160] :) (CD:[2161..2169] 11755311)
        (IN:[2170..2171] -LSB-) (NNP:[2171..2177] PubMed) (HYPH:[2178..2179] -)
        (JJ:[2180..2187] indexed) (IN:[2188..2191] for)
        (NNP:[2192..2200] MEDLINE-RSB-)))
